305 results on '"Biswas, Pinaki"'
Search Results
2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
3. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type
4. A BAR homology domain containing protein, EhABP is the novel interactor of EhAK7, an aurora kinase homolog in E. histolytica
5. In silico analysis of a Skp1 protein homolog from the human pathogen E. histolytica
6. Microbe-Induced Oxidative Stress in Cancer Development and Efficacy of Probiotics as Therapeutics in Preventing Its Onset and Progression
7. Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
8. Isolation and Potential Probiotic Characterization of Lactic Acid Bacteria from an Ethnic Fermented Beverage having Antibacterial Activity against Human Pathogen Entamoeba histolytica
9. Experimental and numerical investigation of differential hardening of cold rolled steel sheet under non-proportional loading using biaxial tensile test
10. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
11. Efficacy of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis With Severe Itch at Baseline and in Subgroups by Baseline Thresholds of Severe Itch: A Post Hoc Analysis of the JADE COMPARE and JADE DARE Clinical Trials
12. Factors Associated with Persistent Efficacy of Abrocitinib without Flare: A Multivariable Analysis of the JADE-REGIMEN Study
13. 529 - Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial
14. 530 - Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
15. Long-Term Efficacy of Abrocitinib in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE EXTEND
16. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
17. Microbe-Induced Oxidative Stress in Cancer Development and Efficacy of Probiotics as Therapeutics in Preventing Its Onset and Progression
18. Oxidative Stress in Entamoeba histolytica
19. Safety of long-term use of linezolid: results of an open-label study
20. Safety of long-term use of linezolid: results of an open-label study.
21. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
22. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies
23. In silico analysis and molecular identification of an anaphase-promoting complex homologue from human pathogen Entamoeba histolytica
24. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
25. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies
26. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
27. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies.
28. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
29. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
30. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
31. Energy absorption behaviour of different grades of steel sheets using a strain rate dependent constitutive model
32. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials.
33. Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
34. Effect of Strengthening Mechanism on Strain-Rate Related Tensile Properties of Low-Carbon Sheet Steels for Automotive Application
35. Abrocitinib Reduces Skin Pain in Adolescent and Adult Patients With Moderate-to-Severe Atopic Dermatitis
36. Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
37. Formation of bainite below the MS temperature: Kinetics and crystallography
38. Prediction of Transformation Strain Using Microtexture Data
39. 32496 Efficacy and safety of abrocitinib according to geographies
40. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
41. Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: a pooled data analysis
42. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
43. Health-related Quality of Life Improvements with Abrocitinib By Clinical Response Status in Patients with Moderate-to-severe Atopic Dermatitis
44. EhSir2c, a Sir2 homolog from the human pathogen Entamoeba histolytica interacts with a DNA repair protein, EhRAD23: Protein-protein interaction, docking and functional study.
45. Clinical Efficacy of Oral Linezolid Compared With Intravenous Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus–Complicated Skin and Soft Tissue Infections: A Retrospective, Propensity Score–Matched, Case-Control Analysis
46. Efficacy of Abrocitinib Rescue Therapy in the Phase 3 Study JADE REGIMEN
47. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary
48. Inference for Constrained Estimation of Tumor Size Distributions
49. Impact de l’abrocitinib sur les démangeaisons, le sommeil, la douleur cutanée et le stress psychologique chez les patients présentant une dermatite atopique modérée à sévère : analyse poolée des essais JADE en monothérapie
50. Efficacité de l’abrocitinib chez les patients avec une atteinte prédominante de la tête et du cou dans les études JADE en monothérapie poolées
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.